Terns Pharmaceuticals (TERN) EBIT: 2020-2024
Historic EBIT for Terns Pharmaceuticals (TERN) over the last 5 years, with Dec 2024 value amounting to -$101.9 million.
- Terns Pharmaceuticals' EBIT fell 24.89% to -$21.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$90.0 million, marking a year-over-year decrease of 45.12%. This contributed to the annual value of -$101.9 million for FY2024, which is 0.67% up from last year.
- According to the latest figures from FY2024, Terns Pharmaceuticals' EBIT is -$101.9 million, which was up 0.67% from -$102.6 million recorded in FY2023.
- Over the past 5 years, Terns Pharmaceuticals' EBIT peaked at -$37.0 million during FY2020, and registered a low of -$102.6 million during FY2023.
- Over the past 3 years, Terns Pharmaceuticals' median EBIT value was -$101.9 million (recorded in 2024), while the average stood at -$88.8 million.
- Per our database at Business Quant, Terns Pharmaceuticals' EBIT plummeted by 65.34% in 2023 and then increased by 0.67% in 2024.
- Yearly analysis of 5 years shows Terns Pharmaceuticals' EBIT stood at -$37.0 million in 2020, then slumped by 34.67% to -$49.9 million in 2021, then decreased by 24.41% to -$62.0 million in 2022, then crashed by 65.34% to -$102.6 million in 2023, then grew by 0.67% to -$101.9 million in 2024.